Médecins généralistes dans le bassin de l'UPEC
Créteil, France
Location status: Recruiting
NCT Number: NCT06527456
In France, cervical cancer is the 12th most common female cancer with nearly 3,000 new cases per year.
Since 2018, a national Organized Cervical Cancer Screening program (DOCCU) has been set up and concerns all asymptomatic women aged 25 to 65.
This program, managed by the Regional Cancer Screening Coordination Centers (CRCDC), invites women who have not taken a sample within the recommended time frame to consult for screening. However, only 59% of patients participated.
The intervention of the general practitioner, an essential player in prevention, could allow for better awareness.
The objective of the INDIGO study is to evaluate the effectiveness of the intervention of a general practitioner on the participation rate in the DOCCU of patients who are not up to date with their screening.
Interested in participating?
Request Info25 year–65 year
All sexes
Interventional
Not applicable
Créteil, France
Location status: Recruiting
This is a cluster-randomized trial. Randomization will be performed at the GP practice level to limit the potential contamination bias between doctors within the same practice. GP practices will be randomized either to the 'usual practice' arm or the 'intervention' arm."
If they are in the "intervention" group, they or one of the professionals in their team will contact the patient (phone call, SMS, email, etc.), to encourage her to make an appointment to carry out the screening. Contact arrangements are left to the discretion of each general practitioner..
If they are in the "Usual practice" group, they will use their usual practices to encourage screening.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
participation of the general practitioner in encouraging cervical cancer screening
Time frame: 12 month
percentage of patients who had a screening Cervical Sample (cytology or HPV test within a timeframe satisfying the HAS recommendations according to age) among patients eligible for screening aged 25 to 65 years
Contact information is provided by the study sponsor or research team.
Camille JUNG
CONTACT
Emilie FERRAT
CONTACT
Centre Hospitalier Intercommunal Creteil
Other
Acronym: INDIGO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05838521
Cervical Cancer, Female Urogenital Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT07216703
Cervical Cancer, Female Urogenital Diseases
Fort Myers, Florida, United States
View Trial DetailsNCT07453459
Cervical Cancer, Communicable Diseases
St Louis, Missouri, United States
View Trial DetailsNCT06465069
Adnexal Diseases, Advanced Solid Tumor
Duarte, California, United States
View Trial Details